The bioactive peptide endothelin causes multiple biologic responses relevant to myocardial and vascular performance after cardiac surgery

Journal of Thoracic and Cardiovascular Surgery

Volumn 123, Issue 6, 2002, Pages 1031-1034

  Spinale, Francis G ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN; ENDOTHELIN RECEPTOR; PEPTIDE DERIVATIVE;

BLOOD VESSEL FUNCTION; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; EDITORIAL; HEART MUSCLE CELL; HEART PERFORMANCE; HEART SURGERY; HUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; VASOCONSTRICTION;

EID: 0036622209     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1067/mtc.2002.124668     Document Type: Article

References (44)

1. Knothe CH, Boldt J, Zickmann B, Ballesteros M, Dapper F, Hempelmann G. Endothelin plasma levels in old and young patients during open heart surgery: correlations to cardiopulmonary and endocrinology parameters. J Cardiovasc Pharmacol. 1992;20:664-70.
2. Kirshbom PM, Page SO, Jacobs MT, Tsui SS, Bello E, Ungerleider RM, et al. Cardiopulmonary bypass and circulatory arrest increase endothelin-1 production and receptor expression in the lung. J Thorac Cardiovasc Surg. 1997;113:777-83.
3. Matheis G, Haak T, Beyersdorf F, Baretti R, Polywka C, Winkelmann BR. Circulating endothelin in patients undergoing coronary artery bypass grafting. Eur J Cardiothorac Surg. 1995;9:269-74.
4. Dorman BH, Bond BR, Clair MJ, Walker CA, Pinosky ML, Reeves ST, et al. Temporal synthesis and release of endothelin within the systemic and myocardial circulation during and following cardiopulmonary bypass: Relation to postoperative recovery. J Cardiovasc Anesth. 2000;14:540-5.
5. Bond BR, Dorman BH, Clair MJ, Walker CA, Pinosky ML, Reeves ST, et al. Endothelin-1 during and after cardiopulmonary bypass: association to graft sensitivity and postoperative recovery. J Thorac Cardiovasc Surg. 2001;122:358-64.
6. Walker CA, Baicu SC, Goldberg AT, Widener CE, Fary DJ, Almany DK, et al. Temporal endothelin dynamics of the myocardial interstitium and systemic circulation in cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2000;120:864-71.
7. Webb DJ. Discovery of the endothelin family of peptides. In: Gray GA, Webb DJ, editors. Molecular biology and pharmacology of the endothelins. Austin: RG Landes: 1995. pp. 3-12.
8. Luscher TF. Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000;102:2434-40.
9. Shiffrin EL, Intengan HD, Thibault G, Touyz RM. Clinical significance of endothelin in cardiovascular disease. Curr Opin Cardiol. 1997;12:354-67.
10. Miyauchi T. Pathophysiology of endothelin in the cardiovascular system. Ann Rev Physiol. 61999;1:391-415.
11. Williamson, DJ, Wallman LL, Jones R, Keogh AM, Scroope F, Penny R, et al. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation. 2000;25:411-8.
12. Roux S, Breu V, Ertel SI, Clozel M. Endothelin antagonism with bosentan: a review of potential applications. J Mol Med. 1999;77:364-76.
13. Hiramatsu T, Forbess J, Miura, T, Roth SJ, Cioffi MA, Mayer JE Jr. Effects of endothelin-1 and endothelin-A receptor antagonist on recovery after hypothermic cardioplegic ischemia in neonatal lamb hearts. Circulation. 1995;92(9 Suppl):II-400-4.
14. Dorman BH, New BR, Bond BR, Mukherjee R, Mukhin YV, McElmurray JH, et al. Myocyte endothelin exposure during cardioplegic arrest exacerbates contractile dysfunction following reperfusion. Anesth Analg. 2000;90:1080-5.
15. Petrossian E, Parry AJ, Reddy VM, Akkersdijk GP, McMullan DM, Thompson L, et al. Endothelin receptor blockade prevents the rise in pulmonary vascular resistance after cardiopulmonary bypass in lambs with increased pulmonary blood flow. J Thorac Cardiovasc Surg. 1999;117:314-23.
16. Pearl JM, Wellmann SA, McNamara JL, Lombardi JP, Wagner CJ, Raake JL, et al. Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function. Ann Thorac Surg. 1999;68:1717-21.
17. Jeffs C, Walker CA, Hendrick JW, Fary DJ, Almany DK, Davis JN, et al. Endothelin receptor subtype A blockade selectively reduces pulmonary pressure after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2001;122:365-70.
18. Verma S, Maitland A, Weisel RD, Li SH, Fedak PWM, Pomroy NC, et al. Hyperglycemia exaggerates ischemia-reperfusion-induced cardiomyocyte injury: reversal with endothelin antagonism. J Thorac Cardiovasc Surg. 2002;123:1120-4.
19. Verma S, Maitland A, Weisel RD, Fedak PWM, Li SH, Mickle DAG, et al. Increased endothelin-1 production in diabetic patients after cardioplegic arrest and reperfusion impairs coronary vascular reactivity: reversal by means of endothelin antagonism. J Thorac Cardiovasc Surg. 2002;123:1114-9.
20. Tonnessen T, Giaid A, Saleh D, Naess PA, Yanagisawa M, Christensen G. Increased in vivo expression and production of endothelin-1 by porcine cardiomyocytes subjected to ischemia. Circ Res. 1995;76: 767-72.
21. Ergul A, Walker CA, Goldberg A, Baicu SC, Hendrick JW, King MK, et al. Endothelin-1 in the myocardial interstitium in heart failure: relation to myocyte endothetin converting enzyme activity and expression. Am J Physiol. 2000;278:H2050-6.
22. Thomas PB, Liu ECK, Webb ML, Mukherjee R, Hebbar L, Spinale FG. Evidence of an endothelin-1 autocrine loop in cardiac myocytes: relation to contractile function with congestive heart failure. Am J Physiol. 1996;271:H2629-37.
23. Davenport AP, Maguire JJ. Is endothelin-induced vasconstriction mediated only by ETA receptors in humans? TIPS. 1994;15:9-11.
24. Davies MG, Klyachkin ML, Kim JH, Hagen P. Endothelin and vein bypass grafts in experimental atherosclerosis. J Cardiovasc Pharmacol. 1993;22:S348-51.
25. Yang Z, Richard V, von Segesser L, Bauer E, Stulz P, Turina M, et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? Circulation. 1990;82:188-95.
26. Mather K, Anderson TJ, Verma S. Insulin action in the vasculature: physiology and pathophysiology. J Vasc Res. 2001;38:415-22.
27. Hopfner RL, Gopalakrishnan V. Endothelin: emerging role in diabetic vascular complications. Diabetologia. 1999;42:1383-94.
28. Goldberg AT, Bond BR, Mukherjee R, New B, Zellner JL, Crawford FA, et al. The endothelin receptor pathway in human LV myocytes and relation to contractility. Ann Thorac Surg. 2000;69:711-5.
29. Ono K, Tsujimoto G, Sakamoto A, Eto K, Masaki T, Ozaki Y, et al. Endothelin A receptor mediates cardiac inhibition by regulating calcium and potassium currents. Nature. 1994;370:301-4.
30. 2+ channel. J Cardiovasc Pharmacol. 1989;13:S106-11.
31. Jones LG, Rozich JD, Tsutsui H, Cooper G. Endothelin stimulates multiple responses in isolated adult ventricular cardiac myocytes. Am J Physiol. 1992;263:H1447-54.
32. 2+]1 transients, pHi, and contraction in ventricular myocytes. Am J Physiol. 1993;265:H793-800.
33. Spinale FG, Walker JD, Mukherjee R, Iannini JP, Keever AT, Gallagher KP. Concomitant endothelin receptor subtype A blockade during the progression of congestive heart failure in rabbits has direct and beneficial effects on left ventricular and myocyte function. Circulation. 1997;95:1918-29.
34. Onishi K, Ohno M, Little WC, Cheng CP. Endogenous endothelin-1 depresses left ventricular systolic and diastolic performance in congestive heart failure. J Pharmacol Exp Ther. 1999;288:1214-22.
35. Suzuki M, Ohte N, Wang ZM, Williams DJ, Little WC, Cheng CP. Altered inotropic response to endothelin-1 in cardiomyocytes from rats with isoproterenol-induced cardiomyopathy. Cardiovasc Res. 1998;39:589-99.
36. New RB, Sampson AC, King MK, Hendrick JW, Clair MJ, McElmurray J, et al. The effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: effects on left ventricular performance, contractility and neurohormonal systems. Circulation. 2000;19:1447-53.
37. Sheu SS, Blaustein MP. Sodium/calcium exchange and control of cell calcium and contractility in cardiac and vascular smooth muscles. In: Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE, editors. The heart and cardiovascular system. New York: Raven Press; 1992.
38. + exchange in ischemiareperfusion. Basic Res Cardiol. 1996;91:191-202.
39. Sholz W, Albus U. Potential of selective sodium-hydrogen exchange inhibitors in cardiovascular therapy. Cardiovasc Res. 1995;29:184-8.
40. +2 exchange. Circ Res. 1989;65:1045-56.
41. + exchange is impaired in cardiac hypertrophy. J Clin Invest. 1997;99:125-35.
42. Khandoui N, Ho J, Karmazyn M. Role of Na(+)-H+ exchange in mediating effects of endothelin-1 on normal and ischemic/reperfused hearts. Circ Res. 1994;75:369-78.
43. Clozel M. Endothelin receptor antagonists: current status and perspectives. J Cardiovasc Pharmacol. 2000;35:S65-8.
44. Torre-Amione G, Young JB, Durand J, Bozkurt B, Mann DL, Kobrin I, et al. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation. 2001;20:973-80.]